The emergence of medications like copyright and Semaglutide signifies a significant shift in how we manage type 2 diabetes. These new therapies belong to a class known as GLP-1 target agonists, which replicate the effects of a natural hormone that manages blood sugar levels and hunger. Initially, developed for diabetes, their effectiveness in facil